tradingkey.logo

Jasper Therapeutics Inc <JSPR.OQ> expected to post a loss of $1.26 a share - Earnings Preview

ReutersFeb 28, 2025 2:19 PM
  • Jasper Therapeutics Inc JSPR.OQ JSPR.O is expected to show no change in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2025

  • ​LSEG's mean analyst estimate for Jasper Therapeutics Inc is for a loss of $1.26 per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts had risen by about 0.5% in the last three months. ​

  • Wall Street's median 12-month price target for Jasper Therapeutics Inc is $64.00​, above​ its last closing price of $5.67. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Dec. 31 2024

-1.23

-1.23

-1.62

Missed

-31.7

Sep. 30 2024

-1.08

-1.07

-1.24

Missed

-15.7

Jun. 30 2024

-1.08

-1.09

-0.97

Beat

10.9​

Mar. 31 2024

-1.23

-1.22

-1.03

Beat

15.9

​​Dec. 31 2023

-1.60

-1.61

-1.50

Beat

7.1

Sep. 30 2023

-1.53

-1.55

-1.60

Missed

-3.1​

Jun. 30 2023

-1.81

-1.50

-1.50

Met

-0.1

Mar. 31 2023

-1.64

-1.62

-1.60

Beat

1.5

This summary was machine generated February 28 at 14:19 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI